Inovalon Holdings, Inc.
Inovalon Holdings, Inc. INOV Peers
See (INOV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INOV | $31.94 | +0.30% | 13.8M | 16.79 | $1.90 | N/A |
| VEEV | $285.35 | -1.58% | 46.6B | 60.58 | $4.71 | N/A |
| GEHC | $71.62 | +0.10% | 32.8B | 15.05 | $4.76 | +0.18% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | +0.18% |
| DOCS | $58.85 | +2.63% | 11.1B | 53.02 | $1.11 | N/A |
| HQY | $111.55 | -1.02% | 9.6B | 82.02 | $1.36 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
| BTSG | $24.11 | +2.60% | 4.2B | 89.30 | $0.27 | N/A |
| BTSGU | $84.17 | +0.62% | 4.1B | N/A | N/A | N/A |
Stock Comparison
INOV vs VEEV Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, VEEV has a market cap of 46.6B. Regarding current trading prices, INOV is priced at $31.94, while VEEV trades at $285.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas VEEV's P/E ratio is 60.58. In terms of profitability, INOV's ROE is +0.03%, compared to VEEV's ROE of +0.14%. Regarding short-term risk, INOV is less volatile compared to VEEV. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs GEHC Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, GEHC has a market cap of 32.8B. Regarding current trading prices, INOV is priced at $31.94, while GEHC trades at $71.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas GEHC's P/E ratio is 15.05. In terms of profitability, INOV's ROE is +0.03%, compared to GEHC's ROE of +0.26%. Regarding short-term risk, INOV is less volatile compared to GEHC. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs GEHCV Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, INOV is priced at $31.94, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas GEHCV's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to GEHCV's ROE of +0.26%. Regarding short-term risk, INOV is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs DOCS Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, DOCS has a market cap of 11.1B. Regarding current trading prices, INOV is priced at $31.94, while DOCS trades at $58.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas DOCS's P/E ratio is 53.02. In terms of profitability, INOV's ROE is +0.03%, compared to DOCS's ROE of +0.22%. Regarding short-term risk, INOV is less volatile compared to DOCS. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs HQY Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, HQY has a market cap of 9.6B. Regarding current trading prices, INOV is priced at $31.94, while HQY trades at $111.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas HQY's P/E ratio is 82.02. In terms of profitability, INOV's ROE is +0.03%, compared to HQY's ROE of +0.05%. Regarding short-term risk, INOV is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SGFY Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, INOV is priced at $31.94, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SGFY's P/E ratio is 70.91. In terms of profitability, INOV's ROE is +0.03%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, INOV is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs RCM Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, INOV is priced at $31.94, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas RCM's P/E ratio is -102.21. In terms of profitability, INOV's ROE is +0.03%, compared to RCM's ROE of -0.02%. Regarding short-term risk, INOV is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs BTSG Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, BTSG has a market cap of 4.2B. Regarding current trading prices, INOV is priced at $31.94, while BTSG trades at $24.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas BTSG's P/E ratio is 89.30. In terms of profitability, INOV's ROE is +0.03%, compared to BTSG's ROE of +0.03%. Regarding short-term risk, INOV is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs BTSGU Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, BTSGU has a market cap of 4.1B. Regarding current trading prices, INOV is priced at $31.94, while BTSGU trades at $84.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas BTSGU's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to BTSGU's ROE of +0.03%. Regarding short-term risk, INOV is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs ONEM Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, INOV is priced at $31.94, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas ONEM's P/E ratio is -7.77. In terms of profitability, INOV's ROE is +0.03%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, INOV is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs PRVA Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, PRVA has a market cap of 2.8B. Regarding current trading prices, INOV is priced at $31.94, while PRVA trades at $23.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas PRVA's P/E ratio is 193.25. In terms of profitability, INOV's ROE is +0.03%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, INOV is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs WGS Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, INOV is priced at $31.94, while WGS trades at $72.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas WGS's P/E ratio is -51.85. In terms of profitability, INOV's ROE is +0.03%, compared to WGS's ROE of -0.17%. Regarding short-term risk, INOV is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs CERT Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, CERT has a market cap of 1.9B. Regarding current trading prices, INOV is priced at $31.94, while CERT trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas CERT's P/E ratio is -588.00. In terms of profitability, INOV's ROE is +0.03%, compared to CERT's ROE of -0.00%. Regarding short-term risk, INOV is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs PINC Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, PINC has a market cap of 1.9B. Regarding current trading prices, INOV is priced at $31.94, while PINC trades at $22.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas PINC's P/E ratio is 22.49. In terms of profitability, INOV's ROE is +0.03%, compared to PINC's ROE of +0.03%. Regarding short-term risk, INOV is less volatile compared to PINC. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs PGNY Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, PGNY has a market cap of 1.9B. Regarding current trading prices, INOV is priced at $31.94, while PGNY trades at $21.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas PGNY's P/E ratio is 38.04. In terms of profitability, INOV's ROE is +0.03%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, INOV is less volatile compared to PGNY. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SDGR Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SDGR has a market cap of 1.8B. Regarding current trading prices, INOV is priced at $31.94, while SDGR trades at $24.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SDGR's P/E ratio is -9.36. In terms of profitability, INOV's ROE is +0.03%, compared to SDGR's ROE of -0.45%. Regarding short-term risk, INOV is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs NXGN Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, INOV is priced at $31.94, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas NXGN's P/E ratio is -266.00. In terms of profitability, INOV's ROE is +0.03%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, INOV is less volatile compared to NXGN. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs PHR Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, PHR has a market cap of 1.6B. Regarding current trading prices, INOV is priced at $31.94, while PHR trades at $26.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas PHR's P/E ratio is -36.15. In terms of profitability, INOV's ROE is +0.03%, compared to PHR's ROE of -0.23%. Regarding short-term risk, INOV is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs GDRX Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, GDRX has a market cap of 1.5B. Regarding current trading prices, INOV is priced at $31.94, while GDRX trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas GDRX's P/E ratio is 58.29. In terms of profitability, INOV's ROE is +0.03%, compared to GDRX's ROE of +0.07%. Regarding short-term risk, INOV is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs OMCL Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, OMCL has a market cap of 1.5B. Regarding current trading prices, INOV is priced at $31.94, while OMCL trades at $31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas OMCL's P/E ratio is 67.39. In terms of profitability, INOV's ROE is +0.03%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, INOV is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs AGTI Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, INOV is priced at $31.94, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas AGTI's P/E ratio is -71.79. In terms of profitability, INOV's ROE is +0.03%, compared to AGTI's ROE of -0.01%. Regarding short-term risk, INOV is less volatile compared to AGTI. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs TDOC Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, TDOC has a market cap of 1.3B. Regarding current trading prices, INOV is priced at $31.94, while TDOC trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas TDOC's P/E ratio is -1.23. In terms of profitability, INOV's ROE is +0.03%, compared to TDOC's ROE of -0.68%. Regarding short-term risk, INOV is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs TXG Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, TXG has a market cap of 1.2B. Regarding current trading prices, INOV is priced at $31.94, while TXG trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas TXG's P/E ratio is -7.25. In terms of profitability, INOV's ROE is +0.03%, compared to TXG's ROE of -0.22%. Regarding short-term risk, INOV is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs EVH Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, EVH has a market cap of 980.3M. Regarding current trading prices, INOV is priced at $31.94, while EVH trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas EVH's P/E ratio is -6.79. In terms of profitability, INOV's ROE is +0.03%, compared to EVH's ROE of -0.11%. Regarding short-term risk, INOV is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs HSTM Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, HSTM has a market cap of 870.9M. Regarding current trading prices, INOV is priced at $31.94, while HSTM trades at $28.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas HSTM's P/E ratio is 45.29. In terms of profitability, INOV's ROE is +0.03%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, INOV is less volatile compared to HSTM. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs NUTX Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, NUTX has a market cap of 677.8M. Regarding current trading prices, INOV is priced at $31.94, while NUTX trades at $122.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas NUTX's P/E ratio is 10.88. In terms of profitability, INOV's ROE is +0.03%, compared to NUTX's ROE of +0.71%. Regarding short-term risk, INOV is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs CTEV Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, CTEV has a market cap of 647.7M. Regarding current trading prices, INOV is priced at $31.94, while CTEV trades at $39.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas CTEV's P/E ratio is -0.54. In terms of profitability, INOV's ROE is +0.03%, compared to CTEV's ROE of -5.18%. Regarding short-term risk, INOV is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs MPLN-WT Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, INOV is priced at $31.94, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to MPLN-WT's ROE of -5.18%. Regarding short-term risk, INOV is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs ACCD Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, INOV is priced at $31.94, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas ACCD's P/E ratio is -3.08. In terms of profitability, INOV's ROE is +0.03%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, INOV is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs SLP Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SLP has a market cap of 554.1M. Regarding current trading prices, INOV is priced at $31.94, while SLP trades at $27.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SLP's P/E ratio is 76.53. In terms of profitability, INOV's ROE is +0.03%, compared to SLP's ROE of +0.04%. Regarding short-term risk, INOV is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SHCR Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, INOV is priced at $31.94, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SHCR's P/E ratio is -3.76. In terms of profitability, INOV's ROE is +0.03%, compared to SHCR's ROE of -0.24%. Regarding short-term risk, INOV is less volatile compared to SHCR. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs DH Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, DH has a market cap of 400.9M. Regarding current trading prices, INOV is priced at $31.94, while DH trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas DH's P/E ratio is -0.85. In terms of profitability, INOV's ROE is +0.03%, compared to DH's ROE of -1.07%. Regarding short-term risk, INOV is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SLGCW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, INOV is priced at $31.94, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, INOV's ROE is +0.03%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, INOV is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SLGC Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, INOV is priced at $31.94, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SLGC's P/E ratio is -3.04. In terms of profitability, INOV's ROE is +0.03%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, INOV is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs MPLN Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, INOV is priced at $31.94, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas MPLN's P/E ratio is -0.23. In terms of profitability, INOV's ROE is +0.03%, compared to MPLN's ROE of -5.18%. Regarding short-term risk, INOV is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs TBRG Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, TBRG has a market cap of 357.9M. Regarding current trading prices, INOV is priced at $31.94, while TBRG trades at $23.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas TBRG's P/E ratio is -19.52. In terms of profitability, INOV's ROE is +0.03%, compared to TBRG's ROE of -0.10%. Regarding short-term risk, INOV is less volatile compared to TBRG. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs NRC Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, NRC has a market cap of 342.2M. Regarding current trading prices, INOV is priced at $31.94, while NRC trades at $15.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas NRC's P/E ratio is 14.73. In terms of profitability, INOV's ROE is +0.03%, compared to NRC's ROE of +0.71%. Regarding short-term risk, INOV is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SPOK Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SPOK has a market cap of 338.8M. Regarding current trading prices, INOV is priced at $31.94, while SPOK trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SPOK's P/E ratio is 21.39. In terms of profitability, INOV's ROE is +0.03%, compared to SPOK's ROE of +0.10%. Regarding short-term risk, INOV is less volatile compared to SPOK. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs HCAT Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, HCAT has a market cap of 285.4M. Regarding current trading prices, INOV is priced at $31.94, while HCAT trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas HCAT's P/E ratio is -3.57. In terms of profitability, INOV's ROE is +0.03%, compared to HCAT's ROE of -0.20%. Regarding short-term risk, INOV is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs TRHC Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, INOV is priced at $31.94, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas TRHC's P/E ratio is -4.27. In terms of profitability, INOV's ROE is +0.03%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, INOV is less volatile compared to TRHC. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs OPRX Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, OPRX has a market cap of 270.4M. Regarding current trading prices, INOV is priced at $31.94, while OPRX trades at $14.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas OPRX's P/E ratio is -17.00. In terms of profitability, INOV's ROE is +0.03%, compared to OPRX's ROE of -0.13%. Regarding short-term risk, INOV is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SMFR Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, INOV is priced at $31.94, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SMFR's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to SMFR's ROE of -0.17%. Regarding short-term risk, INOV is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SOPH Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SOPH has a market cap of 206.8M. Regarding current trading prices, INOV is priced at $31.94, while SOPH trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SOPH's P/E ratio is -3.09. In terms of profitability, INOV's ROE is +0.03%, compared to SOPH's ROE of -0.63%. Regarding short-term risk, INOV is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs CPSI Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, INOV is priced at $31.94, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas CPSI's P/E ratio is -183.80. In terms of profitability, INOV's ROE is +0.03%, compared to CPSI's ROE of -0.18%. Regarding short-term risk, INOV is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs EUDA Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, EUDA has a market cap of 127.8M. Regarding current trading prices, INOV is priced at $31.94, while EUDA trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas EUDA's P/E ratio is -6.37. In terms of profitability, INOV's ROE is +0.03%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, INOV is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SY Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SY has a market cap of 118.6M. Regarding current trading prices, INOV is priced at $31.94, while SY trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SY's P/E ratio is -1.12. In terms of profitability, INOV's ROE is +0.03%, compared to SY's ROE of -0.26%. Regarding short-term risk, INOV is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs AUGX Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, INOV is priced at $31.94, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas AUGX's P/E ratio is -4.99. In terms of profitability, INOV's ROE is +0.03%, compared to AUGX's ROE of -1.13%. Regarding short-term risk, INOV is less volatile compared to AUGX. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs AMWL Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, AMWL has a market cap of 110.5M. Regarding current trading prices, INOV is priced at $31.94, while AMWL trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas AMWL's P/E ratio is -0.69. In terms of profitability, INOV's ROE is +0.03%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, INOV is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs CCLD Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, CCLD has a market cap of 92.3M. Regarding current trading prices, INOV is priced at $31.94, while CCLD trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas CCLD's P/E ratio is -9.91. In terms of profitability, INOV's ROE is +0.03%, compared to CCLD's ROE of +0.21%. Regarding short-term risk, INOV is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs CCLDO Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, CCLDO has a market cap of 90.1M. Regarding current trading prices, INOV is priced at $31.94, while CCLDO trades at $19.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas CCLDO's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to CCLDO's ROE of +0.21%. Regarding short-term risk, INOV is less volatile compared to CCLDO. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs FORA Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, FORA has a market cap of 64.3M. Regarding current trading prices, INOV is priced at $31.94, while FORA trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas FORA's P/E ratio is -17.17. In terms of profitability, INOV's ROE is +0.03%, compared to FORA's ROE of -0.13%. Regarding short-term risk, INOV is less volatile compared to FORA. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs CCLDP Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, INOV is priced at $31.94, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas CCLDP's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to CCLDP's ROE of +0.21%. Regarding short-term risk, INOV is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs BEAT Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, BEAT has a market cap of 55.8M. Regarding current trading prices, INOV is priced at $31.94, while BEAT trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas BEAT's P/E ratio is -2.23. In terms of profitability, INOV's ROE is +0.03%, compared to BEAT's ROE of -3.58%. Regarding short-term risk, INOV is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs BEATW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, BEATW has a market cap of 45.4M. Regarding current trading prices, INOV is priced at $31.94, while BEATW trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas BEATW's P/E ratio is -1.11. In terms of profitability, INOV's ROE is +0.03%, compared to BEATW's ROE of -3.58%. Regarding short-term risk, INOV is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs SNCE Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, INOV is priced at $31.94, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SNCE's P/E ratio is -0.27. In terms of profitability, INOV's ROE is +0.03%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, INOV is less volatile compared to SNCE. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs AKLI Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, INOV is priced at $31.94, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas AKLI's P/E ratio is -0.71. In terms of profitability, INOV's ROE is +0.03%, compared to AKLI's ROE of -0.38%. Regarding short-term risk, INOV is less volatile compared to AKLI. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SHLT Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, INOV is priced at $31.94, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SHLT's P/E ratio is -3.87. In terms of profitability, INOV's ROE is +0.03%, compared to SHLT's ROE of -0.09%. Regarding short-term risk, INOV is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs SHCRW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, INOV is priced at $31.94, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, INOV's ROE is +0.03%, compared to SHCRW's ROE of -0.24%. Regarding short-term risk, INOV is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs RNLX Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, INOV is priced at $31.94, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas RNLX's P/E ratio is -0.33. In terms of profitability, INOV's ROE is +0.03%, compared to RNLX's ROE of +2.93%. Regarding short-term risk, INOV is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs MGRX Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, MGRX has a market cap of 22.5M. Regarding current trading prices, INOV is priced at $31.94, while MGRX trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas MGRX's P/E ratio is -0.48. In terms of profitability, INOV's ROE is +0.03%, compared to MGRX's ROE of -0.73%. Regarding short-term risk, INOV is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs LIFW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, INOV is priced at $31.94, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas LIFW's P/E ratio is -0.02. In terms of profitability, INOV's ROE is +0.03%, compared to LIFW's ROE of -3.08%. Regarding short-term risk, INOV is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs STRM Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, STRM has a market cap of 21.5M. Regarding current trading prices, INOV is priced at $31.94, while STRM trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas STRM's P/E ratio is -2.05. In terms of profitability, INOV's ROE is +0.03%, compared to STRM's ROE of -0.68%. Regarding short-term risk, INOV is less volatile compared to STRM. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs VSEE Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, VSEE has a market cap of 18M. Regarding current trading prices, INOV is priced at $31.94, while VSEE trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas VSEE's P/E ratio is -12.78. In terms of profitability, INOV's ROE is +0.03%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, INOV is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs VSEEW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, VSEEW has a market cap of 16.3M. Regarding current trading prices, INOV is priced at $31.94, while VSEEW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas VSEEW's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, INOV is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs BFRG Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, BFRG has a market cap of 15.8M. Regarding current trading prices, INOV is priced at $31.94, while BFRG trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas BFRG's P/E ratio is -2.21. In terms of profitability, INOV's ROE is +0.03%, compared to BFRG's ROE of -1.63%. Regarding short-term risk, INOV is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs BBLN Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, INOV is priced at $31.94, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas BBLN's P/E ratio is -0.04. In terms of profitability, INOV's ROE is +0.03%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, INOV is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SCNX Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SCNX has a market cap of 13.9M. Regarding current trading prices, INOV is priced at $31.94, while SCNX trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SCNX's P/E ratio is 1.61. In terms of profitability, INOV's ROE is +0.03%, compared to SCNX's ROE of +0.19%. Regarding short-term risk, INOV is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs ONMD Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, ONMD has a market cap of 11.8M. Regarding current trading prices, INOV is priced at $31.94, while ONMD trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas ONMD's P/E ratio is -1.14. In terms of profitability, INOV's ROE is +0.03%, compared to ONMD's ROE of +0.60%. Regarding short-term risk, INOV is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs MSPR Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, MSPR has a market cap of 11.7M. Regarding current trading prices, INOV is priced at $31.94, while MSPR trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas MSPR's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to MSPR's ROE of -3.08%. Regarding short-term risk, INOV is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs ETAO Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, INOV is priced at $31.94, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas ETAO's P/E ratio is -0.01. In terms of profitability, INOV's ROE is +0.03%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, INOV is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs HLTH Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, INOV is priced at $31.94, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas HLTH's P/E ratio is -0.02. In terms of profitability, INOV's ROE is +0.03%, compared to HLTH's ROE of -0.88%. Regarding short-term risk, INOV is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs OTRK Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, OTRK has a market cap of 6.5M. Regarding current trading prices, INOV is priced at $31.94, while OTRK trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas OTRK's P/E ratio is -0.09. In terms of profitability, INOV's ROE is +0.03%, compared to OTRK's ROE of -1.76%. Regarding short-term risk, INOV is less volatile compared to OTRK. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs EUDAW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, EUDAW has a market cap of 5.4M. Regarding current trading prices, INOV is priced at $31.94, while EUDAW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas EUDAW's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, INOV is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs UPH Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, INOV is priced at $31.94, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas UPH's P/E ratio is -0.07. In terms of profitability, INOV's ROE is +0.03%, compared to UPH's ROE of -1.05%. Regarding short-term risk, INOV is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs ZCMD Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, ZCMD has a market cap of 5.3M. Regarding current trading prices, INOV is priced at $31.94, while ZCMD trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas ZCMD's P/E ratio is -8.50. In terms of profitability, INOV's ROE is +0.03%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, INOV is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs PEAR Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, INOV is priced at $31.94, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas PEAR's P/E ratio is -0.08. In terms of profitability, INOV's ROE is +0.03%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, INOV is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs PEARW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, INOV is priced at $31.94, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas PEARW's P/E ratio is -0.00. In terms of profitability, INOV's ROE is +0.03%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, INOV is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs ACON Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, ACON has a market cap of 4M. Regarding current trading prices, INOV is priced at $31.94, while ACON trades at $6.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas ACON's P/E ratio is -0.60. In terms of profitability, INOV's ROE is +0.03%, compared to ACON's ROE of -1.27%. Regarding short-term risk, INOV is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs HCTI Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, HCTI has a market cap of 2.7M. Regarding current trading prices, INOV is priced at $31.94, while HCTI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas HCTI's P/E ratio is -0.01. In terms of profitability, INOV's ROE is +0.03%, compared to HCTI's ROE of +2.95%. Regarding short-term risk, INOV is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs FOXO Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, FOXO has a market cap of 2.2M. Regarding current trading prices, INOV is priced at $31.94, while FOXO trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas FOXO's P/E ratio is -0.05. In terms of profitability, INOV's ROE is +0.03%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, INOV is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs WORX Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, WORX has a market cap of 1.8M. Regarding current trading prices, INOV is priced at $31.94, while WORX trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas WORX's P/E ratio is -0.55. In terms of profitability, INOV's ROE is +0.03%, compared to WORX's ROE of -0.32%. Regarding short-term risk, INOV is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs WGSWW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, WGSWW has a market cap of 1.7M. Regarding current trading prices, INOV is priced at $31.94, while WGSWW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas WGSWW's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to WGSWW's ROE of -0.17%. Regarding short-term risk, INOV is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs CMAX Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, INOV is priced at $31.94, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas CMAX's P/E ratio is -0.00. In terms of profitability, INOV's ROE is +0.03%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, INOV is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs LIFWZ Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, INOV is priced at $31.94, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to LIFWZ's ROE of -3.08%. Regarding short-term risk, INOV is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs ICCT Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, ICCT has a market cap of 1.1M. Regarding current trading prices, INOV is priced at $31.94, while ICCT trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas ICCT's P/E ratio is -0.01. In terms of profitability, INOV's ROE is +0.03%, compared to ICCT's ROE of -14.51%. Regarding short-term risk, INOV is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs OTRKP Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, OTRKP has a market cap of 1M. Regarding current trading prices, INOV is priced at $31.94, while OTRKP trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas OTRKP's P/E ratio is -0.08. In terms of profitability, INOV's ROE is +0.03%, compared to OTRKP's ROE of -1.76%. Regarding short-term risk, INOV is more volatile compared to OTRKP. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs KERNW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, INOV is priced at $31.94, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas KERNW's P/E ratio is -0.00. In terms of profitability, INOV's ROE is +0.03%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, INOV is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs KERN Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, INOV is priced at $31.94, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas KERN's P/E ratio is -0.01. In terms of profitability, INOV's ROE is +0.03%, compared to KERN's ROE of -2.22%. Regarding short-term risk, INOV is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs MSPRZ Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, MSPRZ has a market cap of 88.4K. Regarding current trading prices, INOV is priced at $31.94, while MSPRZ trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to MSPRZ's ROE of -3.08%. Regarding short-term risk, INOV is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs LIFWW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, INOV is priced at $31.94, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas LIFWW's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to LIFWW's ROE of -3.08%. Regarding short-term risk, INOV is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs CMAXW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, INOV is priced at $31.94, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas CMAXW's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, INOV is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs ACONW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, ACONW has a market cap of 21.3K. Regarding current trading prices, INOV is priced at $31.94, while ACONW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas ACONW's P/E ratio is -0.01. In terms of profitability, INOV's ROE is +0.03%, compared to ACONW's ROE of -1.27%. Regarding short-term risk, INOV is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs MSPRW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, MSPRW has a market cap of 7K. Regarding current trading prices, INOV is priced at $31.94, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas MSPRW's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to MSPRW's ROE of -3.08%. Regarding short-term risk, INOV is more volatile compared to MSPRW. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs UTRS Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, UTRS has a market cap of 888. Regarding current trading prices, INOV is priced at $31.94, while UTRS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas UTRS's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, INOV is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for INOV.
INOV vs MTBCO Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, INOV is priced at $31.94, while MTBCO trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas MTBCO's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to MTBCO's ROE of +0.21%. Regarding short-term risk, INOV is less volatile compared to MTBCO. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs MTBC Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, INOV is priced at $31.94, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas MTBC's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to MTBC's ROE of +0.21%. Regarding short-term risk, INOV is less volatile compared to MTBC. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs SMFRW Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, INOV is priced at $31.94, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas SMFRW's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to SMFRW's ROE of -0.17%. Regarding short-term risk, INOV is less volatile compared to SMFRW. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs CNVY Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, INOV is priced at $31.94, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas CNVY's P/E ratio is -71.50. In terms of profitability, INOV's ROE is +0.03%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, INOV is less volatile compared to CNVY. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.
INOV vs CHNGU Comparison
INOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INOV stands at 13.8M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, INOV is priced at $31.94, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INOV currently has a P/E ratio of 16.79, whereas CHNGU's P/E ratio is N/A. In terms of profitability, INOV's ROE is +0.03%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, INOV is less volatile compared to CHNGU. This indicates potentially lower risk in terms of short-term price fluctuations for INOV.